Comparison of Finasteride (Proscar®) and Serenoa repens (Permixon®) in the Inhibition of 5-Alpha Reductase in Healthy Male Volunteers

January 1994 in “European Urology”

Georges Strauch, P Perles, Gerard Vergult, Munir Gabriel, B Gibelin, Stuart Cummings, William Malbecq, Marie-Pierre Malice

TLDR Finasteride works better than Permixon in reducing dihydrotestosterone levels.

This study compared the effectiveness of finasteride and Permixon in inhibiting 5-alpha reductase in healthy male volunteers. Finasteride was found to be more effective than Permixon in reducing serum dihydrotestosterone levels, confirming its potent and specific inhibition of 5-alpha reductase. The study suggests that finasteride may be a more effective treatment for conditions related to 5-alpha reductase, such as benign prostatic hyperplasia.

View this study on karger.com →

research A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia

12 citations , January 1998 in “Drug safety”

research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.

30 citations , August 1992 in “The Journal of Clinical Endocrinology and Metabolism”

Finasteride doesn't affect hormone levels in normal men.